Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has completed dosing in part b of its three-part CYB004-E phase 1 trial. The study is designed to evaluate intravenous N,N-dimethyltryptamine (“IV DMT”) in healthy volunteers. The company also announced that it now plans to move forward with part C of the study, which involves the first-in-human dosing of its proprietary DMT molecule CYB004 and will evaluate IV bolus + infusion regimens of CYB004 in a crossover design. The company expects that findings from both parts of the trial will “provide a more robust pharmacokinetic (‘PK’) and pharmacodynamic (‘PD’) model to optimize dose selection and formulation development for future clinical studies.” According to the announcement, Cybin hopes to have topline data from the completed phase 1 study in Q3 of this year. “We are pleased with the continued progress we are making with our CYB004 program and excited to reach our next key milestone of first-in-human dosing with our novel CYB004 molecule,” said Cybin CEO Doug Drysdale in the press release. “Through part C of the trial, we will have the ability to evaluate CYB004 in humans earlier than expected and potentially demonstrate the advantages of deuteration on pharmacokinetic/pharmacodynamic parameters, enabling a less invasive and more convenient dose form that may eliminate the need for specialized and costly clinical centers for dosing.”
To view the full press release, visit https://ibn.fm/z7uup
About Cybin Inc.
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug-discovery platforms, innovative drug-delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder; the company also has a research pipeline of investigational psychedelic-based compounds. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
BioMedWire is part of the InvestorBrandNetwork